DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes

M. J. Riedel, D. F. Gaddy, A. Asadi, P. D. Robbins, T. J. Kieffer

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that performs a wide array of well-characterized antidiabetic actions, including stimulation of glucose-dependent insulin secretion, upregulation of insulin gene expression and improvements in beta-cell survival. GLP-1-receptor agonists have been developed for treatment of diabetes; however, the short biological half-lives of these peptide-based therapeutics requires that frequent injections be administered to maintain sufficient circulating levels. Thus, novel methods of delivering GLP-1 remain an important avenue of active research. It has recently been demonstrated that self-complimentary, double-stranded, adeno-associated virus serotype-8 (DsAAV8) can efficiently transduce pancreatic beta-cells in vivo, resulting in long-term transgene expression. In this study, we engineered a DsAAV8 vector containing a GLP-1 transgene driven by the mouse insulin-II promoter (MIP). Biological activity of the GLP-1 produced from this transgene was assessed using a luciferase-based bioassay. DsAAV8-MIP-GLP-1 was delivered via intraperitoneal injection and beta-cell damage induced by multiple low dose streptozotocin (STZ) administration. Glucose tolerance was assessed following intraperitoneal glucose injections and beta-cell proliferation measured by PCNA expression. Expression of GLP-1 in Min6 beta-cells resulted in glucose-dependent secretion of biologically active GLP-1. Intraperitoneal delivery of DsAAV8-MIP-GLP-1 to mice led to localized GLP-1 expression in beta-cells and protection against development of diabetes induced by multiple low-dose STZ administration. This protection was associated with significant increase in beta-cell proliferation. Results from this study indicate that expression and secretion of GLP-1 from beta-cells in vivo via DsAAV8 represents a novel therapeutic strategy for treatment of diabetes.

Original languageEnglish (US)
Pages (from-to)171-180
Number of pages10
JournalGene therapy
Volume17
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Bibliographical note

Funding Information:
This work was supported by funding from the Canadian Institutes of Health Research (CIHR), the American Diabetes Association and the Juvenile Diabetes Research Foundation (JDRF; 7-2005-1154). MJR was supported by the Michael Smith Foundation for Health Research (MSFHR), the Canadian Diabetes Association, the Stem Cell Network and the JDRF. DFG was supported by JDRF Postdoctoral Fellowship award 3-2007-728. TJK is a MSFHR senior scholar.

Keywords

  • AAV
  • Adeno-associated virus
  • Diabetes
  • GLP-1
  • Glucagon like peptide-1

Fingerprint Dive into the research topics of 'DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes'. Together they form a unique fingerprint.

Cite this